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Abstract An increasing number of orthopedic operations are
being carried out in an older population in whom the preva-
lence of diabetes is dramatically increasing. People having
surgery with diabetes and hyperglycemia are at increased risk
of post-operative complications. The peri-operative risks have
been well demonstrated for cardiac surgery and, more recent-
ly, for orthopedic surgery. This paper considers the issues
surrounding orthopaedic surgery in patients with diabetes
and the significance and management of hyperglycemia in
the peri-operative period.
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Introduction
The global prevalence and incidence of diabetes is steadily
rising in all populations and at the current rate the
International Diabetes Foundation (IDF) estimates a prevalence
of 9.9% worldwide by 2030. With population growth, this rep-
resents a 50.7% increase in people affected over a 19-year pe-
riod [1]. A personwith diabetes is more likely to require surgery
than a person without and this is particularly notable for ortho-
pedic surgery, which has seen an overall increase in procedures
in this population as a whole [2].
Observational studies show that in the surgical patient, di-
abetes is associated with a higher rate of peri-operative com-
plications such as need for transfusion, pneumonia, delayed
discharge, surgical site infections, and in-hospital mortality
[3]. These poorer outcomes are in part due to higher rates of
co-morbid conditions such as ischemic heart disease, renal
impairment, and hypertension in patients with diabetes [4].
Dysglycemia, which encompasses hyperglycemia, hypogly-
cemia, stress-induced hyperglycemia, and excessive glucose
variability, is increasingly observed and associated with
poorer post-operative outcomes even in those without a prior
diagnosis of diabetes. In fact, several studies have shown post-
operative complications occur more frequently in people with
stress-induced hyperglycemia with no prior diagnosis of dia-
betes than in those with diabetes [5–7].
Effect of Surgery on Glucose Levels
Surgery and anesthesia elicit a stress response that produces
marked neurophysiological changes with release of adrena-
line, noradrenaline, cortisol, glucagon, and growth hormone.
This increase in counter-regulatory hormones and cytokines
raises glucose levels and increases insulin resistance. In sus-
ceptible patients, this may result in significant hyperglycemia
[8]. Additionally, elements of the surgical process such as
disturbed eating patterns due to fasting or post-operative nau-
sea, omission of insulin or hypoglycemic medication, and
complications such as wound infection can all contribute to
dysregulation of glucose homeostasis in the peri-operative
period. The resulting raised, low, or erratic glucose levels have
all been associated with poor outcomes.
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Effect of Glycemia on Outcomes for Orthopedic
Surgery
Hyperglycemia impairs leucocyte function causing
immunocompromise with consequences for superficial and
deep tissue infection as well as overall mortality [9].
The detrimental effects of suboptimal glycemic control
on surgical outcomes and post-operative complications
have been demonstrated across surgical specialities.
Within orthopedics, the subspecialties of spinal surgery,
arthroplasty, and trauma surgery have been most extensive-
ly studied.
Surgical Site Infection
Surgical site infection is the most common hospital acquired
infection and is associated with worse functional outcomes
and increased amputation rates in patients undergoing ortho-
pedic surgery [10, 11]. Rates of surgical site infection are
significantly increased in patients with diabetes, most notably
in those with suboptimal glycemic control. Preoperative
HbA1c levels above 7.0% have been found to be associated
with higher rates of surgical site infection for thoracic and
lumbar spinal instrumentation surgery (35.3% compared with
0.0%) [12]. The incidence of surgical site infections has
also been linked to peri-operative hyperglycemia in peo-
ple without a prior diagnosis of diabetes. In this group,
stress-induced hyperglycemia >200 mg/dL (11.1 mmol/l)
is an independent risk factor for surgical site infection
at 30 days (OR 3.2, 95% CI: 1.3–7.8) even after adjust-
ment for open fractures [13]. Following trauma, a 7-fold
increase in peri-operative infections has been seen with
peri-operative hyperglycemia >220 mg/dL (12.2 mmol/l,
P= 0.0056) [6].
Peri-prosthetic Infection
Although uncommon, occurring in around 1% of
arthroplasties, peri-prosthetic infection is one of the most
devastating orthopedic complications for patients and sur-
geons and may require further surgery to treat effectively
[14]. No significant association has been demonstrated be-
tween peri-operative HbA1c and peri-prosthetic infection
at the hip or knee; however, both pre- and post-operative
hyperglycemia have been associated with this serious com-
plication [15•, 16]. Morning post-operative hyperglycemia
>140 mg/dL(7.8 mmol/L) is associated with a 3-fold in-
creased risk of peri-prosthetic infection (27/285 compared
with 20/582) [17]. In a series of 1565 primary knee
arthroplasties, Jämson and colleagues showed a 4-fold in-
crease in people with a peri-operative glucose >6.9 mmol/
L compared with those with a normal reading of
<6.1 mmol/L [18].
Other Complications, Length of Stay, and Morbidity
It is apparent that glycemia correlates with multiple poor post-
operative outcomes in orthopedic surgery, including mortality.
Raised HbA1c is associated with increased length of hospital
stay and is a predictor of risk for pulmonary embolism follow-
ing orthopedic surgery [19]. Pre-operative HbA1c over 6.5%
has been shown to be a significant risk factor for surgical
outcome with a poor post-operative recovery rate following
cervical laminoplasty (OR 2.6, P=0.02) [20]. Undergoing
primary joint arthroplasty with an HbA1c above 7.0% carries
an increased mortality (HR 1.3, P=0.01) [15•].
Glycemic Management and Surgical Outcomes
Despite the above associations, the key question is whether
treating hyperglycemia reduces complications and improves
these outcomes. There are no randomised studies in orthope-
dic surgery; however, one observational study by Agos et al.
demonstrated that implementation of an evidence-based stan-
dard to control hyperglycemia reduced the rate of surgical site
infection in people undergoing hip and knee replacement
surgery [21••].
Treating hyperglycemia in the peri-operative period has
been shown to reduce complications in other surgical disci-
plines. Trussel and colleagues demonstrated reductions in sur-
gical site infection with tight peri-operative glycemic control
in people having coronary artery bypass grafting (CABG)
surgery [22]. Similarly, Furnary and colleagues showed reduc-
tions in mortality and deep infection rates by treating people
with diabetes undergoing cardiac surgery; the lowest rates
seen in people targeted under 150mg/dL (8.3 mmol/L) [23].
In general surgery, Umpierrez showed that lower rates of hy-
perglycemia, using a basal bolus regime, was associated with
reduced incidence of wound infection, pneumonia, bacter-
emia, and respiratory and acute renal failure [24]. These lim-
ited data have provided the basis for the American Association
of Clinical Endocrinologists (AACE) and American Diabetes
Association (ADA) guidelines, the Joint British Diabetes
Society (JBDS) guidelines, and others all advocating treat-
ment of hyperglycemia for hospitalized patients peri-
operatively [25–27]. The target glucose ranges for these
guidelines are summarized in Table 1.
The Effect of Diabetes and Its Complications
on Peri-operative Risk in Orthopedics
Diabetes irrespective of glycemia is associated with greater
surgical risk because of the higher incidence of co-morbid
conditions, including obesity, sleep apnea, hypertension, in
addition to the micro- and macrovascular complications that
are associated with the condition. In people with diabetes,
13 Page 2 of 11 Curr Diab Rep (2017) 17: 13
surgery at the hip, knee, ankle, and elbow is associated with
higher rates of post-operative infection, need for transfusion,
pneumonia, urinary tract infection, length of stay, non-routine
discharge, and in-hospital mortality [28, 29].
The condition of diabetes, in a recent meta-analysis, has
shown an increased surgical site infection rate from pooled US
data with OR 1.26 (95% CI 1.01–1.66) for arthroplasty and 1.6
(CI 1.10–2.32) for spinal surgery after accounting for impact of
hyperglycemia and adjusting for BMI [30]. Interestingly, diabe-
tes treated with insulin has been linked to increased 30-day
readmission rates for people undergoing arthroplasty [31].
This may relate to disease chronicity, which has been associated
with poor outcomes in cervical laminoplasty for people with 10
or more years duration of diabetes [20].
Neuropathy and vascular insufficiency, which may compli-
cate diabetes, presents challenges for lower limb and particu-
larly foot and ankle surgery, for which a modified approach is
taken. Subsequent hospital-acquired foot ulceration in high
risk feet can take several months to heal and superadded in-
fection may complicate these ulcers, increasing the risk of
peri-prosthetic infection and amputation [32].
Diabetic Cardiovascular Disease and Surgery
A 2- to 3-fold increased prevalence of cardiovascular disease
in people with diabetes makes surgery a higher-risk undertak-
ing for this group [33, 34]. Hyperglycemia causes an osmotic
diuresis, and the resulting hypovolemia and electrolyte distur-
bance may be further exacerbated by nausea and vomiting
caused by anesthetic agents. The result may be tachycardia,
hypokalemia, and hypomagnesemia with the resulting ar-
rhythmias contributing to the increased peri-operative cardio-
vascular mortality in these patients [35].
As cardiac ischemia may be ‘silent’ in people with diabe-
tes, a baseline ECG should be carried out in all people with
diabetes prior to surgery. The threshold for cardiology referral
and further investigations should be determined locally but
based on the relevant national guidelines.
The following sections deal with peri-operative clinical as-
sessment of elective surgery from pre-hospitalization through
to discharge including pre-operative assessment, hospital ad-
mission, theater and recovery, and the post-operative period.
The considerations of pumps, steroid-induced hyperglycemia,
and emergency surgery are also discussed.
Prehospitalization Assessment
Surgical Outpatients
It is clear from the previous discussion that the orthopedic
surgeon’s decision to proceed to surgery should include some
assessment of the surgical risk to the patient with diabetes
taking into account their diabetic complications and other co-
morbidities. High risk patients should be highlighted
prompting early review, usually in a pre-assessment clinic to
assess and optimize medication, glycemia, and blood pressure
control prior to surgery. Specialist referrals for detailed assess-
ment and optimization of diabetes or its cardiac or renal com-
plications can be initiated at this stage.
One of the aims throughout the peri-operative process is to
reduce the glycemic variability that may result from meal
disruption and surgery itself.
Glycemic variability can be described as the degree to
which glucose values fluctuate between peaks and troughs
for an individual. There is no universally agreed ideal meth-
od to calculate it at present. It has emerged as a contributing
factor for macro- and microvascular complications in the
outpatient setting in people with both type 1 and type 2
diabetes. However, its impact in hospitalized patients has
yet to be fully established. There are studies highlighting
its importance in the critical care and peri-operative setting.
A retrospective study by Egi et al. looked at 7049 critically
ill patients with glucose measurements taken at least 4-hour-
ly. Glucose variability was an independent risk factor in
predicting mortality in ICU and hospitalized patients with
Table 1 Peri-operative glucose
targets in national guidelines Group Target (noncritically ill patients) Publication year
Joint British Diabetes Societies
For NHS Diabetes (26)
6–10 mmol/L (108–180 mg/dL) target
4–12 mmol/L (72–216 mg/dL) acceptable
2012
AACE/ADA/Endocrine society (25) <140 mg/dL (7.8 mmol/L) and a
random BG of less than 180 mg/dL
(10.0 mmol/L)
Consider lower targets in those with
previously tight control
2009
Canadian Diabetes Association (27) Fasting 5.0-8.0 mmol/L (90–144 mg/dL)
Random <10 mmol/L (if safely achievable)
2013
The Association of Anaesthetists of Great
Britain and Ireland (56)
6–10 mmol/L (108–180 mg/dL) target
(intra-operatively)
6–12 mmol/L (108–216 mg/dL) acceptable
2015
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an OR of 1.28 per mmol/LSD for variability and 1.21 per
mmol/L for glucose level, hinting that glycemic variability is
at least as important as hyperglycemia this patient group
[36]. Although there are no prospective randomized trials
demonstrating the impact of glycemic variability on ortho-
pedic complications or that reducing variability improves
outcomes, it is sensible to aim to limit glycemic variability
until evidence to the contrary emerges.
In order to minimize glycemic variability, it is advised that
patients with diabetes are prioritized on morning or afternoon
lists, thereby limiting the period of fasting and disruption to
normal meal times. JBDS guidelines suggest 95% of patients
with diabetes should be on the first third of elective lists with
avoidance of elective evening surgery altogether [26]. The
regimen used to manage inpatient hyperglycemia also impacts
on glucose variability, which is discussed later in this article.
Accessible electronic systems can facilitate priorities in care
pathways by highlighting those people with diabetes. A flag
initiated from first contact and visible throughout the peri-
operative journey can be used to prompt actions such as priority
list position. The glycemic and non-glycemic considerations
throughout the peri-operative period are highlighted in Fig. 1.
Preoperative Assessment
Screening for Diabetes
Since a suspected 1% of the UK population and up to 3% of
people in the US are thought to have undiagnosed diabetes, it
is increasingly common for diabetes to be detected on pre-
operative bloods on the day of surgery. However, screening
for diabetes in the pre-assessment period is not routine, but
should be considered. One prospective study of people under-
going elective noncardiac surgery found hyperglycemia in
over 25% (118/493) of those without a prior diagnosis of
diabetes on the morning of surgery [37].
Failure to identify and manage diabetes and hyperglycemia
pre-operatively has been shown to increase the risk of com-
plications with higher requirement for resuscitation, re-intuba-
tion, longer post-operative ventilation, and increased mortality
[7, 38]. Indeed, studies to date suggest that the risk in those not
known to have diabetes and those with stress or pre-operative
glycemia is several fold greater than those with diabetes.
Guidelines at present do not recommend diabetes screening
of patients being assessed for all types of elective surgery. The
National Institute of Clinical Excellence (NICE) suggests test-
ing for diabetes in people admitted to hospital at risk of the
disease; however, this is generally limited to emergency ad-
missions [39]. The ADA recommends screening for people
over the age of 45 years and earlier in those with
BMI>25 kg/m2 with age adjustment for higher risk ethnic
groups [40]. However, for elective orthopedic surgery, one
meta-analysis suggests that it should be considered to mini-
mize complications in the peri-operative period [41••]. HbA1c
is increasingly being measured for this purpose with a value of
48 mmol/L(6.5%) or more diagnosing the condition in a
symptomatic patient [42]. As the prevalence of diabetes rises,
there is a potentially huge economic burden, which may result
from adopting screening for diabetes in surgical pathways. If
screening were adopted for all surgical pathways, this expense
would need to be justified with randomized controlled trials.
Although the amalgamated research in all non-cardiac surgery
may be insufficient to recommend screening in national guide-
lines, it should be adopted in orthopedic surgery and vascular
surgery based on current evidence [41••].
Glycemic Assessment of the Diabetic Patient
Measurement of HbA1c highlights those with poorly con-
trolled diabetes allowing optimization of glycemic control pri-
or to surgery. It may be necessary to delay elective surgery to
facilitate this.
There is no evidence-based guideline published that pre-
cludes surgery above a particular value for HbA1c; however,
most guidelines advise below 8–9% (68–75 mmol/mol) for
elective orthopedic surgery as a safe target [26]. In view of
the complications correlated with raised HbA1c in orthope-
dics, some institutions may opt for lower pre-operative values
than guidelines recommend. However, data suggests a signif-
icant proportion of patients scheduled for arthroplasty will
take over 6 months to attain the guideline target HbA1c and
for others it may not be feasible [20, 43].
Complications and Comorbidities
The complications of diabetes should be actively assessed and
optimized in view of the associated peri-operative risk they
contribute. For patients undergoing foot and ankle surgery, it
is essential to undertake a preoperative neurovascular assess-
ment of the feet in addition. Neuropathy is associated with
increased surgical site infection rates even in those without
diabetes. High risk feet can be identified without any equip-
ment using a quick and simple bedside tool, the ‘Ipswich
touch test’, prompting pressure relief as soon as convalescent
[44]. Pre-operative revascularization may be necessary in
some people with significant peripheral vascular disease.
The pre-operative workup for people with diabetes under-
going surgery is covered in detail in both the Joint British
Diabetes Societies and ADA guidelines and the additional
management considerations relating to diabetes should be
incorporated into local orthopedic pathways and proformas
to prevent omission of these elements during the peri-
operative period. Clear written instructions on the alter-
ations to medications according to local guidelines should
be given to patients at pre-assessment.
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Fig. 1 Orthopedic peri-operative pathway decision tool
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A self-reporting checklist for patients with diabetes to com-
plete can alert staff to potential problems for further attention.
Hospital Admission
Glycemic Control and Monitoring
The aims of peri-operative glycemic control are avoiding hy-
poglycemia, marked hyperglycemia, electrolyte disturbance,
and the diabetic emergencies of hyperosmolar hyperglycemic
state (HHS) and diabetic ketoacidosis (DKA). The target
range that is most effective in achieving these aims remains
a matter of debate.
The NICE-SUGAR trial and a series of studies challenged
the dogma for tight glycemic control outside of the critical
care or cardiology setting with increased mortality attributed
to higher rates of hypoglycemia [45]. The emphasis is increas-
ingly on adapting the glycemic target to the individual patient
and their circumstances. Published guidelines focus on safe
rather than tight control with JBDS promoting glucose targets
between 6 and 10 with 4–12 mmol/L as an acceptable range.
A selection of differing peri-operative targets by country are
displayed in Table 1.
Close monitoring in the peri-operative period is required to
detect and manage glucose excursions and is advised before
meals or 4–6 hourly in patients who are not eating. Blood tests
on admission should include a laboratory glucose or capillary
blood glucose with point of care testing. There should be clear
local policies to optimize glycemic control in the hospital
throughout the peri-operative period with methods governed
by the individual patient circumstances, the policy and re-
sources of the institution, and clinician’s judgement.
Fasting and Enhanced Recovery
Prolonged fasting results in increased insulin resistance in
both those with and without diabetes. Higher insulin resis-
tance is associated with poor wound healing, higher compli-
cation rates, and increased length of hospital stay. The degree
of insulin resistance is greater in larger or more complex op-
erations and those with greater blood loss and through meta-
bolic pathways, it contributes to hyperglycemia [46]. A meta-
analysis has shown insulin resistance may be attenuated by
half with administration of oral or IV glucose, associated with
reductions in length of stay [47]. Pre-operative oral carbo-
hydrate treatment has been widely adopted as part of an
enhanced recovery program; a multimodal approach to
peri-operative care, which includes early mobilization, mini-
mization of the fasting period, and optimizing pain relief.
Enhanced recovery programmes have been shown to reduce
length of stay and post-operative complications, most nota-
bly in colorectal surgery [48].
Although enhanced recovery programmes show improved
post-operative outcomes, there is limited evidence demonstrat-
ing the benefits of pre-operative carbohydrate loading specifi-
cally within these programmes. The impact of carbohydrate
loading in improving a range of post-operative outcomes has
been examined in a Cochrane review of 27 randomized con-
trolled trials, including 4 orthopedic studies. The authors of this
review concluded that preoperative carbohydrate loading offers
small reductions in length of stay; however, complications and
well-being are not significantly impacted [49].
There is a paucity of data on the potential impact of pre-
operative carbohydrate loading on those with diabetes. A small
case controlled study by Gustaffson et al. found no delay in
gastric emptying following a carbohydrate drink for subjectswith
type 2 diabetes compared with healthy volunteers. In this study,
peak glucose concentrations occurred later and were higher
(13.4 ± 0.5 compared with 7.6±0.5 mmol/l; P≤0.01) [50].
With the aforementioned concerns about increased compli-
cation rates related to peri-operative hyperglycemia, the ad-
ministration of carbohydrate drinks in people with diabetes
requires further study before it is implemented for this group,
particularly in orthopedic surgery. The exclusion of people
with insulin treated diabetes from these programmes [51]
may limit further detailed study of this group.
Immobility and Pressure Ulcers
Pressure ulcers are a problem in surgery, causing pain, reduced
quality of life, and prolonged hospital admission; diabetes can
increase the risk of pressure ulcers 3-fold. Pressure ulcers fol-
lowing hip surgery can have devastating consequences with
associated complication rates ranging from 16 to 46% and an
increased mortality rate of 27% [52].
Prevention is the most effective way to approach this prob-
lem with simple inspection found to be more effective than
currently advocated scoring systems. As the majority of these
ulcers develop in-hospital, often on the day of surgery, it is
vital that preventative measures commence on admission [53].
The period of immobility should be minimized and feet
should be carefully inspected preoperatively for ulceration,
which may act as a port for infection that people with diabetes
may not self-report due to neuropathy. Multidisciplinary team
involvement is crucial in those who develop ulceration as
resultant hyperglycemia in those with infected ulcers can cre-
ate a vicious cycle by delaying wound healing.
Theater and Recovery
Glucose Targets and Glucose Management
There are limited data examining the effect of intra-operative
glycemic control on post-operative outcomes with available
13 Page 6 of 11 Curr Diab Rep (2017) 17: 13
studies carried out in cardiac surgery. Doenst et al. showed an
intra-operative peak glucose reading >20mmol/L(360mg/dL)
to be an independent risk factor for poor post-operative
outcome and mortality in people with diabetes (OR,
1.20; CI, 1.08–1.32) and without diabetes (OR, 1.12;
CI, 1.06–1.19; per mmol/L increase in glucose) [54].
Ouattara et al. found poor intra-operative glycemic con-
trol, defined as 4 or more consecutive blood glucose
values over 11.1 mmol/L(200 mg/dL), to confer a
higher risk of cardiac and noncardiac post-operative
complications [55]. The Association of Anesthetists of
Great Britain and Ireland (AAGBI) advise an intra-
operative glucose target of 6–10 mmol/L with a peak
up to 12 mmol/L for less well controlled patients.
Ketone testing is advised with intra-operative glucose
readings over 12 mmol/L[56].
Glucose testing remains central to maintaining glycemic
control and should be carried out prior to induction of anes-
thesia, then hourly for operations of over 2 hours. For
prolonged fasting with more than 1 missed meal or operations
over 3 hours, an insulin infusion may be required. In these
instances, a glucose, insulin, potassium (GIK) regime may be
used, where the 3 elements are combined in a single bag for
infusion. However, many institutions favor the variable rate
intravenous insulin infusion (VRIII), where insulin and
glucose with or without potassium are delivered as sep-
arate infusions with titration of the insulin every 1–
2 hours. This requires close monitoring and regular ad-
justment as potentially dangerous glucose excursions
can occur when the infusions are mismatched. In a
small study looking at patients undergoing cardiothorac-
ic surgery, the VRIII was found to offer more stable
glycemic control than the GIK regime [57]; however, there
is little evidence in support of one method over the other, and
local policy should be followed. VRIII should commence at
least 2 hours prior to surgery to allow time for abnormal glu-
cose readings to stabilize.
For people on a long-acting basal insulin, local pol-
icies usually advise continuation of the basal insulin
with the variable rate insulin infusion. This facilitates
transition back to the usual regime when oral intake is
reinstated. If the basal insulin is discontinued preopera-
tively, it must be given 30 to 60 minutes prior to any
intravenous insulin being taken down because of the
short half-life of intravenous insulin in order to reduce
the risk of diabetic ketoacidosis.
Pumps
For people on continuous subcutaneous insulin infusion (in-
sulin pumps) undergoing day case surgery, there is evidence
that this may be safely continued intra-operatively for up to
3 hours whilst maintaining safe glycemic control post-
operatively with the support of the specialist endocrine team
[58]. Alternatively, subcutaneous basal insulin may be used at
a dose equivalent to the background insulin dose administered
over 24 hours on the pump.
There are a few considerations when planning to con-
tinue insulin pumps intra-operatively. It is generally rec-
ommended that pumps be removed for X-ray, CT, or
MRI scanning; however, covering the pump with a lead
shield may be sufficient for X-rays. The need for imag-
ing intra-operatively is often pre-empted and subcutane-
ous insulin may be a good alternative to pump use in
these circumstances. Additionally, electro-cautery and the
presence of flammable anesthetic mixtures with oxygen or
nitrous oxide in the operating room may affect the function
of the pump, so the manufacturer’s guidance should be
reviewed and followed [59].
Foot Protection
Pressure damage leading to subsequent ulceration may
begin within a few hours of sustained pressure; there-
fore repositioning has been advised at least every
2 hours intra-operatively where possible. An array of
pressure relieving devices are available, from foam mat-
tresses to inflatable heel supports, which can reduce the
development of pressure ulcers by up to 70%. However,
there is no single, recommended device [60] and most
orthopedic units employ gel pads or inflatable air-boots.
Limb surgery is discounted since the operated limb is
mobile intra-operatively.
Antibiotics
The role for peri-operative antibiotic prophylaxis in joint
arthroplasty is well documented [61, 62]. People who
are morbidly obese have differences in antibiotic phar-
macodynamics and pharmacokinetics, making their effi-
cacy less predictable in these people. Obesity is associ-
ated with increased rates of surgical site infection and
studies by Dowsey and Choong have shown it to be an
independent risk factor for peri-prosthetic infection at
both hip and knee [63, 64]. As a significant proportion
of people with type 2 diabetes will be obese, weight-
adjusted dosing should be considered.
A few antibiotics have been studied in this population,
including aminoglycosides, vancomycin, daptomycin, and li-
nezolid. Weight-adjusted antibiotic dosing is not widely prac-
ticed in the UK or recommended in the guidance; however,
the additional risk of obesity is considered in the dosing advice
in Australian and US guidance. The American Association of
Surgeons (AAOS) recommend weight-adjusted dosing for a
range of antibiotics with a double dose of 2g cephalexin for
patients over 80kg [65].
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Post-operative Period
Managing Medication
Post-operatively, diet and usual diabetes medications should
be restarted as soon as possible; however, there are a few oral
agents for which clinical circumstances should be considered
before reinstating. Metformin carries a risk of lactic acidosis,
particularly in those with renal insufficiency. It should be
omitted in patients who develop acute kidney injury until renal
function returns to near baseline or eGRF is above 30mL/min/
1.73m2. It should also be withheld in sepsis, congestive car-
diac failure, and significant hepatic impairment, all of which
may be associated with hypoxia increasing the risk of lactic
acidosis. Thiazolidinediones such as pioglitazone should not
be restarted if significant fluid retention or congestive cardiac
failure have developed or when there are liver function abnor-
malities. In patients who have not resumed a normal diet,
sulphonylureas such as gliclazide may be withheld because
of their insulin secretory effects with potential for causing
hypoglycemia. A smaller dose may be initiated and titrated
up as oral intake returns to normal. A cautious re-introduction
should also be considered where there has been a kidney in-
jury, as reduced renal excretion can further augment and pro-
long hypoglycemia. Recent studies have demonstrated the
safety and efficacy of DPP4 inhibitors, the gliptins, in people
with mild to moderate hyperglycemia (200 mg/dl) [66]. In
view of the potential problems with sulphonylureas, it is likely
that the use of these agents will become more widespread.
Insulin infusions should continue until eating has resumed.
On recommencing usual insulin treatment, the subcutaneous
insulin dose should be administered 30 minutes prior to
discontinuing the intravenous infusion, which has a 5–10min-
ute half-life to minimize the risk of DKA and glucose
excursions.
Treating Hyperglycemia
Following surgery, management of hyperglycemia remains
important both for people with diabetes and those with
stress-induced hyperglycemia. Due to its breadth of usability,
insulin remains the main agent for controlling hyperglycemia
for in-hospital patients, and can be used regardless of comor-
bidities or altered clinical states such as impaired renal func-
tion and decompensated cardiac failure. Correction doses of
insulin may be used in insulin-naïve people, but titrating doses
of subcutaneous insulin referred to in the US as sliding scale
are not advised. A recent meta-analysis demonstrated these
corrective subcutaneous doses do not offer tighter glycemic
control for hospitalized patients and are associated with higher
rates of hyperglycemia than a range of other regimes without
any significant reduction in length of hospital stay [67]. Due to
these observed increases in glucose variability, the
subcutaneous ‘sliding scale’ should not be used as the sole
method of glycemic control, but may still be used to supple-
ment other regimes.
Hypoglycemia
Hypoglycemia is unpleasant for patients and associated with
higher mortality rates and longer hospital length of stay. It is
important to remain vigilant to this risk and check capillary
glucose in patients in whom an altered mental state may oth-
erwise be attributed to delirium or drowsiness secondary to
concomitant analgesia following surgery. With its associated
risks, hypoglycemia can be a barrier to intensifying glucose
treatment.
In the case of missed meals or interrupted nutrition, nurse
driven protocols and automated management decision tools
for the omission of sulphonylureas and prandial insulin should
be implemented locally to reduce the risk of iatrogenic hypo-
glycemia and standardize care.
Specialist Teams
It is increasingly common for elderly orthopedic patients to be
managed by an orthogeriatrician to focus on the medical as-
pects of care across the peri-operative period. While this has
improved the overall medical treatment, the specific impact
for quality of care for people with diabetes has not been stud-
ied. Specialist diabetes nursing teams often have a lower
threshold for discharge and can considerably reduce length
of stay for elective procedures with significant cost-saving
implications [68]. Their input at key points in the peri-
operative pathway has been shown to be beneficial, and clear
pathways for pre-operative referral and post-operative in-
volvement should be developed locally.
Special Circumstances
Steroids
Steroid injections are an important adjunct in managing mus-
culoskeletal diseases. Intra-articular injections are most fre-
quently carried out for osteo-arthritis [69], with the knee joint
the most common site of injection, followed by shoulder,
wrist, ankle, and elbow joints [70]. This route allows symp-
tomatic relief whilst minimizing systemic corticosteroid ef-
fects. However, due to concerns over peri-prosthetic infec-
tion, their use is often avoided within 3 months of elective
surgery [71].
Synthetic steroids mimic endogenous glucocorticoid, bind-
ing to the nuclear glucocorticoid receptor, affecting transcrip-
tion of anti-inflammatory mediators. These effects may last for
months. The effects of intra-articular steroid injections on the
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hypothalamic-pituitary-adrenal axis have been most widely
studied [72], but they may also affect glucose metabolism in
a similar manner to oral steroids. This effect is exerted in a
number of ways from increased insulin resistance to direct
effects on pancreatic beta cell function. The resulting hyper-
glycemiamay be asymptomatic or result in osmotic symptoms
and fatigue. It often resolves spontaneously, but if persistent
after steroid withdrawal, it is termed steroid induced diabetes.
The few studies examining the effect of intra-articular ste-
roid injection on glycemic control suggest that there are only
short-term effects, which vary depending on the site and type
of injection [73, 74]. While the hyperglycemic effects are gen-
erally not sustained long enough to affect injection site elec-
tive orthopedic surgery due restrictions imposed by infection
risk, it is worth noting that there may be an impact on glucose
for up to 5 days following injection [73]. Therefore, people
with previously controlled type 2 diabetes should have home
glucose monitoring if elective surgery of another joint is
planned with 2 weeks of steroid injection or closely monitored
if emergency surgery is required.
The JBDS advise measuring glucose at least once daily, pref-
erably prior to the evening meal, in those given steroids not
known to have diabetes and if above 12 mmol/L(216 mg/dL),
treating to maintain glucose levels between 6 and 10, accepting
a pragmatic range of 4–12 mmol/l. They suggest HbA1C be
measured in patients at high risk of steroid-induced diabetes,
and a baseline level should be taken in those with pre-existing
diabetes prior to commencement of steroids [75].
It is recommended to increase the frequency of glucose
monitoring to 4 times a day and to commence treatment for
2 consecutive glucose readings above 12 mmol/L. For hyper-
glycemia resulting from intra-articular steroid injection, as
with multiple daily steroid doses, oral agents are unlikely to
control the hyperglycemia, and a subcutaneous insulin regime
is preferred. A pragmatic approach would be to commence
basal insulin and titrate this according to glucose values. In
this case, a morning NPH insulin such as humulin I or
insulatard is suggested, starting at 10 units daily titrating up
by 10–20% every 24 hours until glucose readings are on target
[75]. The local community diabetes teammay be contacted for
further advice and support.
Emergency Surgery
People with diabetes are more likely to require emergency
orthopedic procedures for a number of reasons.
Hypoglycemia and peripheral neuropathy increase the likeli-
hood of falls, and bonemineral density is affected, particularly
in those with type 1 diabetes, increasing the fracture risk fur-
ther. The orthopedic surgeon may also be involved in the
management of diabetic foot emergencies depending on the
local service setup.
In the emergency setting, glycemic control remains crucial
to reducing post-operative complications; however, the clini-
cal situation restricts the time to fully optimize patients. In
these settings, intravenous insulin given as a variable rate in-
fusion remains the most effective way to achieve
normoglycemia in the peri-operative period. The local proto-
col often advises continuation of the usual background insulin
for those on basal insulin to facilitate prompt return to a nor-
mal regime postoperatively.
Where possible, DKA should be treated as a priority and
the fluid and electrolyte disturbances of HHS should be re-
duced or corrected prior to surgery.
Conclusions
People with diabetes require particular consideration in plan-
ning orthopedic surgery. It can be difficult to put guidelines
into practice across the multistep peri-operative process; how-
ever, significant improvements in care, with patient benefits
and cost saving implications are possible. Specialist in-patient
teams who can examine local processes, along with design
and implementation of clear local pathways across the surgical
process are key in minimizing the harm to this vulnerable
group of patients.
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